Explore News By Topic

03/25/2020

THE SECOND ANNUAL PCF BLACK HISTORY MONTH ASSIST CHALLENGE SETS NEW FUNDRAISING RECORD BY RAISING MORE THAN $500,000 FOR PROSTATE CANCER RESEARCH

LOS ANGELES, Calif., March 25, 2020 – In its sophomore year, the Second Annual Prostate Cancer Foundation Black History Month Assist Challenge more than tripled its fundraising efforts, compared to 2019,  by raising more than $500,000 to combat prostate cancer, a disease that affects more than three million men in... Read More

03/18/2020

KRISTEN BELL SELECTS THE WINNERS OF THE PROSTATE CANCER FOUNDATION’S 3RD ANNUAL TRUE LOVE CONTEST

LOS ANGELES, Calif., March 18, 2020 – The Prostate Cancer Foundation (PCF) and actress Kristen Bell announced today, the winners of the 3rd Annual TRUE Love Contest that honors caregivers and supporters of prostate cancer patients. From more than a hundred inspirational stories, Bell chose two heartfelt stories – one... Read More

02/13/2020

Cleveland Clinic Researchers Validate Link Between Genetic Variant and Poor Outcomes in Men with Advanced Prostate Cancer

February 13, 2020, CLEVELAND: In a new Cleveland Clinic-led study published in JAMA Oncology, researchers show that the a testosterone-related genetic variant – HSD3B1(1245C) – is associated with more aggressive disease and shorter survival in men with metastatic prostate cancer. This study – the first clinical trial validation of the... Read More

02/04/2020

THE PROSTATE CANCER FOUNDATION RECRUITS NBA AND NHL TEAMS TO JOIN FORCES FOR THE 2ND ANNUAL PCF BLACK HISTORY MONTH ASSIST CHALLENGE

LOS ANGELES, Calif., February 4, 2020 – The Prostate Cancer Foundation (PCF) has drafted teams from the NBA and NHL to help fight prostate cancer with the 2nd Annual PCF Black History Month Assist Challenge. Teams participating during February include Atlanta Hawks, Brooklyn Nets, Chicago Bulls, Detroit Pistons, Indiana Pacers,... Read More

01/29/2020

THE PROSTATE CANCER FOUNDATION AND KRISTEN BELL HONOR CAREGIVERS WITH ITS 3RD ANNUAL TRUE LOVE CONTEST

LOS ANGELES, Calif., January 29, 2020 – Beginning February 1st, the Prostate Cancer Foundation (PCF) will launch its 3rd Annual TRUE Love contest to honor family and caregivers for their diligent work in caring for their loved ones living with prostate cancer. TRUE pays tribute to the unsung heroes –... Read More

11/11/2019

The Prostate Cancer Foundation Adds Four New Centers Of Excellence To Serve And Honor Veterans With Prostate Cancer

LOS ANGELES, Calif., Nov. 11, 2019 /PRNewswire/ -- Four new Prostate Cancer Foundation (PCF) Centers of Excellence (COEs) have joined the PCF's dedicated network of centers executing the ambitious mission of improving the care for U.S. Veterans with prostate cancer. With the addition of the new centers, the PCF has established 10 COEs... Read More

09/26/2019

THE PROSTATE CANCER FOUNDATION ANNOUNCES A COLLABORATIVE GRANTS PROGRAM IN PROSTATE CANCER RESEARCH

LOS ANGELES, Calif., September 26, 2019 – The Prostate Cancer Foundation (PCF) today announced a collaboration with Pfizer Global Medical Grants to fund approximately $2 million in research grants through a Competitive Research Grants Program, which  is focused on investigating talazoparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in prostate cancer.... Read More

09/04/2019

The Prostate Cancer Foundation Made History by Lighting U.S. Landmarks “Blue” Across All 50 States to Illuminate Prostate Cancer Issue

LOS ANGELES, Calif., September 4, 2019 – For the first time in American history, U.S. landmarks in all 50 states (and the District of Columbia) were lit blue on September 3 to kick-off Prostate Cancer Awareness Month. The Prostate Cancer Foundation’s (PCF) “Light It Blue” campaign is a national effort... Read More

07/30/2019

FDA Approves Bayer’s Nubeqa® (darolutamide), a New Treatment for Men with Non-Metastatic Castration-Resistant Prostate Cancer

WHIPPANY, N.J., July 30, 2019 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) today approved Nubeqa® (darolutamide), an androgen receptor inhibitor (ARi), for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC).  The FDA approval is based on the Phase III ARAMIS trial evaluating Nubeqa plus androgen deprivation... Read More

05/30/2019

THE PROSTATE CANCER FOUNDATION AND MAJOR LEAGUE BASEBALL KICK OFF 24th ANNUAL HOME RUN CHALLENGE ON JUNE 1st

One in 9 U.S. men will be diagnosed with prostate cancer which is equivalent to at least one player on a baseball team One man dies from prostate cancer every 17 minutes which is roughly equivalent to one player per inning More than 31,000 men will die from prostate cancer... Read More